Journal ArticleDOI
Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study.
James L. Januzzi,Javed Butler,Naveed Sattar,Jialin Xu,Wayne Shaw,Norman Rosenthal,Michael Pfeifer,Kenneth W. Mahaffey,Bruce Neal,Michael K. Hansen +9 more
TLDR
Plasma IGFBP7 concentrations predicted renal and cardiac events among participants with type 2 diabetes and high cardiovascular risk and more data are needed regarding circulating IGF BP7 and progression of diabetic kidney disease and its complications.Abstract:
OBJECTIVE To analyze the association between concentrations of plasma insulin-like growth factor binding protein 7 (IGFBP7) with renal and cardiac outcomes among participants with type 2 diabetes and high cardiovascular risk. RESEARCH DESIGN AND METHODS Associations between IGFBP7 levels and clinical outcomes were assessed among participants in the Canagliflozin Cardiovascular Assessment Study (CANVAS) with type 2 diabetes and high cardiovascular risk. RESULTS Among CANVAS participants, 3,577 and 2,898 had IGFBP7 measured at baseline and 1 year, respectively. Per log-unit higher concentration, baseline IGFBP7 was significantly associated with the composite renal end point of sustained 40% reduction in estimated glomerular filtration rate, need for renal replacement therapy, or renal death (hazard ratio [HR] 3.51; P CONCLUSIONS Plasma IGFBP7 concentrations predicted renal and cardiac events among participants with type 2 diabetes and high cardiovascular risk. More data are needed regarding circulating IGFBP7 and progression of diabetic kidney disease and its complications.read more
Citations
More filters
Journal ArticleDOI
Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.
Muthiah Vaduganathan,Naveed Sattar,Jialin Xu,Javed Butler,Kenneth W. Mahaffey,Bruce Neal,Wayne Shaw,Norm Rosenthal,Michael Pfeifer,Michael K. Hansen,James L. Januzzi +10 more
TL;DR: The CANVAS (CANagliflozin cardioVascular assessment study) biomarker substudy as discussed by the authors evaluated the prognostic significance of baseline biomarker measurements, the long-term trajectory of each, and response to canaglifloclozin on key cardiovascular and kidney outcomes.
Journal ArticleDOI
Critical Overview of Hepatic Factors That Link Non-Alcoholic Fatty Liver Disease and Acute Kidney Injury: Physiology and Therapeutic Implications
TL;DR: It is hypothesized that the effects of NAFLD are not only limited to the structural and functional changes in the liver but may also involve the entire body via the hepatic factors, e.g., playing an important role in the development of AKI.
Journal ArticleDOI
Insulin-like growth factor-binding protein-7 (IGFBP7) links senescence to heart failure
Liying Zhang,David Smith,Mohammad Al-Khalaf,Alice Blet,Qiujiang Du,Jordan Bernick,Michael Gong,Xuejing Chi,Yena Oh,Malaika Roba-Oshin,Elizabeth Coletta,Michel Félétou,Anthony O. Gramolini,Kyoung-Han Kim,Thais Coutinho,James L. Januzzi,Benoit Tyl,André Ziegler,Peter P. Liu +18 more
TL;DR: In this paper , the authors showed that myocardial IGFBP7-regulated senescence pathways may have broad therapeutic potential for heart failure in elderly populations, by selectively targeting IGFBP-regulated pathways.
Journal ArticleDOI
IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial
Pankaj Puar,Nikhil Mistry,Kim A. Connelly,Andrew T. Yan,Adrian Quan,Hwee Teoh,Yi Pan,Rajnikant Verma,David J. Hess,Subodh Verma,C. David Mazer +10 more
TL;DR: In this paper , an exploratory sub-analysis of the EMPA-HEART CardioLink•6 randomized controlled trial evaluated the association between serum levels of IGFBP7 and empagliflozin-mediated left ventricular mass regression.
Posted ContentDOI
Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors
K. Young,Robert J. Massey,Scott J. Pilla,Maggie A. Stanislawski,Deirdre K Tobias,Andrew McGovern,Adem Y. Dawed,Angus G. Jones,Ewan R. Pearson,John M Dennis +9 more
TL;DR: The authors performed a pre-registered systematic review of meta-analysis studies, randomized control trials, and observational studies evaluating clinical and biological features associated with heterogenous treatment effects for SGLT2-inhibitor and GLP1-receptor agonist therapies, considering glycaemic, cardiovascular, and renal outcomes.
References
More filters
Journal ArticleDOI
Canagliflozin and cardiovascular and renal events in type 2 diabetes
Bruce Neal,Vlado Perkovic,Vlado Perkovic,Kenneth W. Mahaffey,Dick de Zeeuw,Greg Fulcher,Ngozi Erondu,Wayne Shaw,Gordon Law,Mehul Desai,David R. Matthews +10 more
TL;DR: Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.
Journal ArticleDOI
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic,Vlado Perkovic,Meg Jardine,Meg Jardine,Bruce Neal,Bruce Neal,Bruce Neal,Severine Bompoint,Hiddo J.L. Heerspink,David M. Charytan,David M. Charytan,Robert Edwards,Rajiv Agarwal,Rajiv Agarwal,George L. Bakris,Scott Bull,Christopher P. Cannon,Christopher P. Cannon,George Capuano,Pei-Ling Chu,Dick de Zeeuw,Tom Greene,Adeera Levin,Carol A. Pollock,David C. Wheeler,Yshai Yavin,Hong Zhang,Bernard Zinman,Gary Meininger,Barry M. Brenner,Kenneth W. Mahaffey +30 more
TL;DR: In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years.
Journal ArticleDOI
Diabetic kidney disease
Merlin C. Thomas,Michael Brownlee,Katalin Susztak,Kumar Sharma,Karin Jandeleit-Dahm,Sophia Zoungas,Peter Rossing,Per-Henrik Groop,Mark E. Cooper +8 more
TL;DR: What is now known about the molecular pathogenesis of CKD in patients with diabetes and the key pathways and targets implicated in its progression are summarized and the opportunities to develop new interventions through urgently needed investment in dedicated and focused research are explored.
Journal ArticleDOI
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Vlado Perkovic,Vlado Perkovic,Dick de Zeeuw,Kenneth W. Mahaffey,Greg Fulcher,Ngozi Erondu,Wayne Shaw,Terrance D. Barrett,Michele A. Weidner-Wells,Hsiaowei Deng,David R. Matthews,Bruce Neal +11 more
TL;DR: Canagliflozin treatment was associated with a reduced risk of sustained loss of kidney function, attenuated eGFR decline, and a reduction in albuminuria in patients with type 2 diabetes.
Journal ArticleDOI
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
Bruce Neal,Vlado Perkovic,Dick de Zeeuw,Kenneth W. Mahaffey,Greg Fulcher,Peter P. Stein,Mehul Desai,Wayne Shaw,Joel Jiang,Frank Vercruysse,Gary Meininger,David R. Matthews +11 more
TL;DR: The CANVAS trial as discussed by the authors evaluated the effects of canagliflozin on the risk of cardiovascular disease and to assess safety and tolerability in patients with inadequately controlled T2DM and increased cardiovascular risk.